Bellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report published on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Bellerophon Therapeutics stock opened at $0.01 on Tuesday. The firm has a 50-day moving average of $0.04 and a 200-day moving average of $0.04. The company has a market cap of $149,206.00, a price-to-earnings ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a one year low of $0.01 and a one year high of $0.10.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.